Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Jun 24;20(1):94.
doi: 10.1186/s12902-020-00576-7.

Fasting in diabetes treatment (FIT) trial: study protocol for a randomised, controlled, assessor-blinded intervention trial on the effects of intermittent use of a fasting-mimicking diet in patients with type 2 diabetes

Elske L van den Burg  1 , Marjolein P Schoonakker  2 , Petra G van Peet  2 , M Elske van den Akker-van Marle  3 , Ko Willems van Dijk  4   5 , Valter D Longo  6   7 , Hildo J Lamb  8 , Mattijs E Numans  2 , Hanno Pijl  4
Affiliations
Randomized Controlled Trial

Fasting in diabetes treatment (FIT) trial: study protocol for a randomised, controlled, assessor-blinded intervention trial on the effects of intermittent use of a fasting-mimicking diet in patients with type 2 diabetes

Elske L van den Burg et al. BMC Endocr Disord. .

Erratum in

Abstract

Background: Caloric restriction is an effective way to treat Type 2 diabetes (T2D). However, chronic and severe restriction of food intake is difficult to sustain and is known to promote slower metabolism. Intermittent and frequent fasting can exert similar metabolic effects, but may be even more challenging for most patients. A fasting-mimicking diet (FMD) is low in calories, sugars and proteins, but includes relatively high levels of plant based complex carbohydrates and healthy fats. The metabolic effects of such a diet mimic the benefits of water-only fasting. The effects of a FMD applied periodically in T2D patients are still unknown. The Fasting In diabetes Treatment (FIT) trial was designed to determine the effect of intermittent use (5 consecutive days a month during a year) of a FMD in T2D patients on metabolic parameters and T2D medication use compared to usual care.

Methods: One hundred T2D patients from general practices in the Netherlands with a BMI ≥ 27 kg/m2, treated with lifestyle advice only or lifestyle advice plus metformin, will be randomised to receive the FMD plus usual care or usual care only. Primary outcomes are HbA1c and T2D medication dosage. Secondary outcomes are anthropometrics, blood pressure, plasma lipid profiles, quality of life, treatment satisfaction, metabolomics, microbiome composition, MRI data including cardiac function, fat distribution and ectopic fat storage, cost-effectiveness, and feasibility in clinical practice.

Discussion: This study will establish whether monthly 5-day cycles of a FMD during a year improve metabolic parameters and/or reduce the need for medication in T2D. Furthermore, additional health benefits and the feasibility in clinical practice will be measured and a cost-effectiveness evaluation will be performed.

Trial registration: The trial was registered on ClinicalTrials.gov. Identifier: NCT03811587. Registered 21th of January, 2019; retrospectively registered.

Keywords: Cost-effectiveness; Diabetes mellitus, type 2; Diet therapy; Fasting; Fasting-mimicking diet; Glycated hemoglobin a.

PubMed Disclaimer

Conflict of interest statement

Health~Holland, the Dutch Diabetes Foundation and L-Nutra, as the funders, have no role in the design or conduct of the study nor in the preparation, review or approval of the manuscripts.

VL is founder and shareholder of L-Nutra; his shares are destined to the Create Cures Foundation and other charitable and research organizations. HP has shares in a company that has invested in L-Nutra.

Figures

Fig. 1
Fig. 1
Timeline of assessments from T0 (baseline) to T8, also in relation to the timing of the FMD
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cornelis MC, Hu FB. Gene-environment interactions in the development of type 2 diabetes: recent progress and continuing challenges. Annu Rev Nutr. 2012;32:245–259. - PubMed
    1. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014;383(9933):1999–2007. - PMC - PubMed
    1. van Ommen B, Wopereis S, van Empelen P, van Keulen HM, Otten W, Kasteleyn M, et al. From Diabetes Care to Diabetes Cure—The Integration of Systems Biology, eHealth, and Behavioral Change. Front Endocrinol (Lausanne). 2018;8(381). - PMC - PubMed
    1. Taylor R, Barnes AC. Translating aetiological insight into sustainable management of type 2 diabetes. Diabetologia. 2017:1–11. - PMC - PubMed
    1. Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;36(4):1047–1055. - PMC - PubMed

Publication types

MeSH terms

Associated data